Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $6.94B | $6.33B | +9.60% |
Cost of Revenue | $2.01B | $1.83B | +9.77% |
Net Income | $1.91B | $1.82B | +4.73% |
EPS (Basic) | $4.18 | $3.94 | +6.09% |
EPS (Diluted) | $4.18 | $3.93 | +6.36% |
SG&A Expense | $1.69B | $1.59B | +6.75% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $14.36B | $14.11B | +1.78% |
Current Assets | $6.28B | $6.22B | +0.96% |
Total Liabilities | $9.12B | $9.03B | +1.01% |
Current Liabilities | $1.7B | $1.61B | +5.85% |
Stockholders' Equity | $5.23B | $5.08B | +3.07% |
Cash & Equivalents | $1.71B | $1.75B | -2.28% |
Long-Term Debt | $6.57B | $6.55B | +0.34% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $2.05B | $1.46B | +40.66% |
Investing Cash Flow | $-441M | $-567M | +22.22% |
Financing Cash Flow | $-1.92B | $-2.71B | +29.39% |
Share Buybacks | $1.3B | $857M | +52.28% |
D&A | $374M | $365M | +2.47% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 27.5% | — | — |
ROE | 36.4% | — | — |
ROA | 13.3% | — | — |
Current Ratio | $3.691 | — | — |
Debt to Equity | $1.743 | — | — |
Other companies in Pharmaceuticals